Portal de investigación
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Cita
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. (EFC17504). Sanofi-Aventis Recherche & Développement. 2024IP:FRANCISCO CARLOS PÉREZ MIRALLES.